Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (134)	11/9/1998 8:44:00 AM
From: yosi s	Read Replies (4) \| Respond to of 1386

This is the way I see a potential for AGIS Agis may buy out Pharmos. To get into US market. They get quick listing. 2. they expand their market. 3. Use their contacts with Pharmaceutical company that they know to get HU 211 deal fast. 4. Co-market with partner HU 211. ( some analogie to TEVA MARION deal) 5. their Israeli same culture as Pharmos will not alienate its research team. Probably bring it aboard. 6. Pharmos will benefit. they do not have to worry about cash follow and forhter ways to raise monies. The two companis benefit each other, Agis is small enough that HU 211 revenues will explode its market cap. Yet big enough to take out Pharmos. Especially if this involves stock swap not buy out. Both entities come together. In order to make it real Agis continue to buy into Pharmos in the short to nedium term..... Best regards Again speculation on my part. Yosi